Table 4 Clinical and laboratory findings in patients with rheumatoid arthritis and different disease activity and controls
From: Impact of disease activity on impaired glucose metabolism in patients with rheumatoid arthritis
RA pts with DAS28-ESR ≥ 5.1 (N = 46) | RA pts with DAS28-ESR < 5.1 (N = 44) | P valuea | P valuea Controls vs. | ||
|---|---|---|---|---|---|
RA pts with DAS28-ESR ≥ 5.1 vs. < 5.1 | RA pts with DAS28-ESR ≥ 5.1 | RA pts with DAS28-ESR < 5.1 | |||
Age (years) | 52.8 ± 10.7 | 52.1 ± 9.2 | ns | ns | ns |
BMI (kg/m2) | 25.6 ± 4.7 | 25.7 ± 3.8 | ns | ns | ns |
Female, n (%) | 40/46 (87.0) | 38/44 (86.4) | ns | ns | ns |
Hypertension, n (%) | 12/46 (26.1) | 16/44 (36.4) | ns | ns | ns |
WC (cm) | 87.4 ± 12.9 | 86.4 ± 11.8 | ns | ns | ns |
Waist-to-hip ratio | 0.85 ± 0.08 | 0.83 ± 0.08 | ns | ns | ns |
MetS, n (%) | 12/46 (26.1) | 7/44 (15.9) | ns | ns | ns |
ESR (mm/h) | 40 (31–62) | 14 (10–29) | 0.000 | 0.000 | ns |
CRP (mg/l) | 12 (5.4–20) | 3.1 (1.5–5.3) | 0.000 | 0.000 | ns |
IL-6 (pg/ml) | 12.8 (4.4–24) | 3.2 (2.0–11) | 0.003 | 0.000 | 0.005 |
Glycemia (mmol/l) | 4.97 ± 0.6 | 4.63 ± 0.6 | 0.046 | ns | ns |
Insulin (pmol/l) | 79 (58–120) | 57 (39–91) | 0.004 | 0.000 | ns |
C-peptide (pmol/l) | 960 (680–1130) | 700 (465–860) | 0.011 | 0.003 | ns |
HOMA2-IR | 1.7 (1.2–2.5) | 1.3 (0.9–1.9) | 0.003 | 0.000 | ns |
HOMA2-IR > 1 (%) | 39/46 (84.0) | 28/44 (63.6) | 0.021 | 0.002 | ns |
HOMA2-%B | 150 (118–195) | 143 (115–184) | ns | ns | ns |
HOMA2-%S | 61 (40–85) | 81 (54–123) | 0.004 | 0.000 | ns |
DAS28-ESR | 6.08 ± 0.79 | 3.51 ± 0.85 | 0.000b | ||
RA duration (years) | 8.5 (4–13) | 10 (5–13) | nsb | ||
GC therapy, n (%) | 30/46 (65.2) | 29/44 (65.9) | nsb | ||
GC doses (mg/day) | 6.2 (5.0–10) | 5 (5–10) | nsb | ||
GC therapy (years) | 3.3 (2.0–6.0) | 5 (3–6) | nsb | ||